Vaxcyte (PCVX) Long-Term Investments (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Long-Term Investments data on file, last reported at $1.0 billion in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $1.0 billion, down 21.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 21.5% YoY), and the FY2025 annual result was $881.7 million, down 36.46% from the prior year.
• Long-Term Investments advanced to $1.0 billion in Q1 2026 per PCVX's latest filing, from $881.7 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $1.4 billion in Q4 2024 and troughed at $4.0 million in Q3 2022.
• A 5-year average of $544.1 million and a median of $399.2 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments tumbled 89.99% in 2022, then soared 4138.47% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $26.5 million in 2022, then jumped by 512.73% to $162.7 million in 2023, then soared by 752.93% to $1.4 billion in 2024, then plunged by 36.46% to $881.7 million in 2025, then gained by 13.88% to $1.0 billion in 2026.
• Business Quant data shows PCVX's Long-Term Investments at $1.0 billion in Q1 2026, $881.7 million in Q4 2025, and $959.3 million in Q3 2025.